Clinical Trial Update: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in advanced Non-Small Cell Lung Cancer is evaluating whether selecting patients by the fraction of ctDNA can guide immunotherapy treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING